Alterity Therapeutics Limited – NASDAQ:ATHE
Founder-led company
Alterity Therapeutics Limited stock price today
$5.05
+1.90
+60.83%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Alterity Therapeutics Limited stock price monthly change
+56.22%
month
Alterity Therapeutics Limited stock price quarterly change
+56.22%
quarter
Alterity Therapeutics Limited stock price yearly change
+22.18%
year
Alterity Therapeutics Limited key metrics
Market Cap | 20.74M |
Enterprise value | N/A |
P/E | -1.2 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 6505.88 |
Price/Book | 60.23 |
PEG ratio | -0.07 |
EPS | N/A |
Revenue | 3.69M |
EBITDA | -11.17M |
Income | -9.27M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -5759.47% |
Oper. margin | -9521.95% |
Gross margin | -24.77% |
EBIT margin | -9521.95% |
EBITDA margin | -302.31% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlterity Therapeutics Limited stock price history
Alterity Therapeutics Limited stock forecast
Alterity Therapeutics Limited financial statements
| Sep 2021 | 852.43K | -2.37M | -279.06% |
|---|---|---|---|
| Dec 2021 | 857.07K | -2.39M | -279.06% |
| Mar 2022 | 1.03M | -2.34M | -226.58% |
| Jun 2022 | 954.26K | -2.16M | -226.58% |
| 2026 | 4.96M | -2.41B | -48556.59% |
|---|---|---|---|
| 2027 | 755.93K | -176.00M | -23283.75% |
Analysts Price target
Financials & Ratios estimates
| Jun 2022 | 41362611 | 5.89M | 14.25% |
|---|---|---|---|
| Sep 2022 | 21351410 | 3.34M | 15.67% |
| Dec 2022 | 33382930 | 5.27M | 15.81% |
| Jun 2023 | 27317636 | 4.50M | 16.49% |
| Jun 2022 | -1.26M | -89K | -29K |
|---|---|---|---|
| Mar 2023 | -3.90M | -5K | 125K |
| Jun 2023 | -6.19M | -26.58K | -40K |
| Mar 2024 | 0 | 0 | 8.25M |
Alterity Therapeutics Limited alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 11 |
| Nov 2023 | 11 |
| Dec 2023 | 11 |
| Jan 2024 | 11 |
| Feb 2024 | 11 |
| Mar 2024 | 11 |
| Apr 2024 | 11 |
| May 2024 | 11 |
| Jun 2024 | 11 |
| Jul 2024 | 11 |
Alterity Therapeutics Limited other data
0.10%
+0.07%
of ATHE is owned by hedge funds
242.34K
+176.23K
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 27 Aug 2021 Issue date: 3 Mar 2022 |
Grant Filling date: 23 Apr 2021 Issue date: 26 Oct 2021 |
Grant Filling date: 13 Mar 2020 Issue date: 9 Mar 2021 |
Application Filling date: 13 Mar 2020 Issue date: 17 Sep 2020 |
| Quarter | Transcript |
|---|---|
| Q2 2021 25 Feb 2021 | Q2 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Geoffrey Paul Kempler B.Sc, B.Sc. (1955) Co-Founder & Non-Executive Chairman | $994,160 |
Dr. David A. Stamler M.D. (1961) Chief Executive Officer | $436,000 |
Ms. Kathryn J. E. Andrews (1967) Chief Financial Officer | $250,300 |
-
What's the price of Alterity Therapeutics Limited stock today?
One share of Alterity Therapeutics Limited stock can currently be purchased for approximately $5.05.
-
When is Alterity Therapeutics Limited's next earnings date?
Unfortunately, Alterity Therapeutics Limited's (ATHE) next earnings date is currently unknown.
-
Does Alterity Therapeutics Limited pay dividends?
No, Alterity Therapeutics Limited does not pay dividends.
-
How much money does Alterity Therapeutics Limited make?
Alterity Therapeutics Limited has a market capitalization of 20.74M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2.63% to 4.02M US dollars.
-
What is Alterity Therapeutics Limited's stock symbol?
Alterity Therapeutics Limited is traded on the NASDAQ under the ticker symbol "ATHE".
-
What is Alterity Therapeutics Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Alterity Therapeutics Limited?
Shares of Alterity Therapeutics Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Alterity Therapeutics Limited's key executives?
Alterity Therapeutics Limited's management team includes the following people:
- Mr. Geoffrey Paul Kempler B.Sc, B.Sc. Co-Founder & Non-Executive Chairman(age: 70, pay: $994,160)
- Dr. David A. Stamler M.D. Chief Executive Officer(age: 64, pay: $436,000)
- Ms. Kathryn J. E. Andrews Chief Financial Officer(age: 58, pay: $250,300)
-
Is Alterity Therapeutics Limited founder-led company?
Yes, Alterity Therapeutics Limited is a company led by its founder Mr. Geoffrey Paul Kempler B.Sc, B.Sc..
-
How many employees does Alterity Therapeutics Limited have?
As Jul 2024, Alterity Therapeutics Limited employs 11 workers.
-
When Alterity Therapeutics Limited went public?
Alterity Therapeutics Limited is publicly traded company for more then 21 years since IPO on 29 Sep 2003.
-
What is Alterity Therapeutics Limited's official website?
The official website for Alterity Therapeutics Limited is alteritytherapeutics.com.
-
Where are Alterity Therapeutics Limited's headquarters?
Alterity Therapeutics Limited is headquartered at 460 Bourke Street, Melbourne, VIC.
-
How can i contact Alterity Therapeutics Limited?
Alterity Therapeutics Limited's mailing address is 460 Bourke Street, Melbourne, VIC and company can be reached via phone at +61 3 9349 4906.
Alterity Therapeutics Limited company profile:
Alterity Therapeutics Limited
alteritytherapeutics.comExchange:
NASDAQ
Full time employees:
10
Industry:
Biotechnology
Sector:
Healthcare
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
460 Bourke Street
Melbourne, VIC 3000
Melbourne, VIC 3000
CIK: 0001131343
ISIN: US02155X2053
CUSIP: 02155X106
